On October 20, 2021 Herantis Pharma Plc ("Herantis or the Company"), focusing on disease modifying therapies for debilitating neurodegenerative diseases reported that it will October 26th, 2021 host an R&D Update Webinar (Press release, Herantis Pharma, OCT 20, 2021, View Source;2021,c3436290 [SID1234591571]). Herantis’ CEO Dr. Craig Cook and CSO Dr. Henri Huttunen will share progress in advancing Herantis’ HER-096 and rhCDNF programs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The R&D update will cover:
Information about Herantis’ novel biomarker focused development program
Data on efficient blood brain barrier (BBB) crossing
Results from pre-clinical experiments showing potent neuroprotective effects
Update on progress of its programs including non-invasive routes of administration
Registration Details:
Herantis Pharma’s R&D Update Webinar
Registered Here
The webcast will also be available under "Company Live Presentations" in the Investors section of the Herantis’ website at www.herantis.com/news-events/video-presentations/. There will also have an opportunity to ask questions in a live Q&A session with speakers. A replay of the webcast will be archived on Herantis’ website following the presentation.
About the Speakers
Dr. Craig Cook, MD, CEO of Herantis
Dr. Craig Cook, MD, is a medical doctor with an MBA from the London Business School and brings more than 20 years of experience in the international pharmaceutical and biotechnology sectors. Dr. Cook’s career has included increasingly senior roles in drug development and commercialization at major life science companies such as Eli Lilly, Johnson & Johnson, Novartis and EMD Serono, as well as entrepreneurial success in several healthcare initiatives. He was CEO of Midatech Pharma PLC, a dual Nasdaq and AIM listed biotech company, before deciding to join Herantis Pharma in 2020. He has worked across several therapeutic areas including neurology, immunology, and oncology.
Dr. Henri Huttunen, CSO of Herantis
Henri Huttunen co-founded Herantis Pharma Plc. in 2008 and served as the company’s founding CEO for the first two years. Dr. Huttunen is currently the Chief Scientific Officer of Herantis. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, and Massachusetts General Hospital, Harvard Medical School (USA). Dr. Huttunen has a PhD in biochemistry from the University of Helsinki and 25 years of experience in neuroscience research. While he was an adjunct professor, Dr. Huttunen lead an academic research group focusing on molecular mechanisms of neurodegenerative diseases at the Neuroscience Center, University of Helsinki.